Rituximab

Patients with new or relapsing granulomatosis with polyangiitis or microscopic polyangiitis should receive rituximab over cyclophosphamide, according to new recommendations from the Pan American League of Associations for Rheumatology.

The FDA has cleared an investigational new drug application for AlloNK in combination with rituximab to treat systemic lupus erythematosus in patients with active lupus nephritis, according to a press release from Artiva Biotherapeutics.

In this video, Jakub Svoboda, MD, discusses a study presented at ASCO Annual Meeting that evaluated rituximab maintenance for young patients with mantle cell lymphoma.

CHICAGO - In this video, Reid Merryman, MD, discusses updates on a trial testing the combination of epcoritamab, rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma.

Remission induction strategies based on rituximab and cyclophosphamide each demonstrate similar risks for kidney failure and death in patients with ANCA-associated vasculitis, according to data published in Arthritis & Rheumatology.

CHICAGO — A split-dose approach to the standard R-CHOP chemotherapy regimen resulted in a 71% complete response rate among older adults with newly diagnosed diffuse large B-cell lymphoma, results from a phase 2 study showed.

Current treatment strategies for patients with central nervous system vasculitis are not based on high-grade scientific evidence but rather expert opinion, according to a speaker at the Biologic Therapies Summit.

DESTIN, Fla. — Despite advances in biologic therapies, “excess steroid use” remains a mainstay of treatment for patients with ANCA-associated vasculitis, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

The FDA approved polatuzumab vedotin-piiq in combination with rituximab, cyclophosphamide, doxorubicin and prednisone as first-line therapy for patients with certain types of B-cell lymphoma.